A number of treatment trials have demonstrated benefit ... compared two of the more commonly used therapies for CIDP: IV immunoglobulin (IVIg) and IV methylprednisolone. The authors performed ...
In conclusion, we consider that the available data indicate that IVIg is not a lost cause for the therapy of MS 15,16, and that clinical trials are therefore warranted to determine if a ...
a leading provider of specialty infusion therapy, announced today that it has been selected by GC Biopharma as a limited distribution partner for ALYGLO™, an FDA-approved immunoglobulin ...